- TransMedics Group (TMDX, Financial) has granted stock options and RSUs as inducement awards to new employees.
- The grants include 9,940 stock options with a $121.31 exercise price and 6,670 RSUs.
- Both the options and RSUs have specific vesting schedules tied to continued employment.
TransMedics Group, Inc. (TMDX), a leader in organ transplant technology, has announced the issuance of inducement grants to 15 newly recruited employees as of May 21, 2025. The incentive package includes a total of 9,940 non-qualified stock options, each priced at $121.31 per share, aligning with the closing price of the stock on Nasdaq on the grant date.
The stock options come with a vesting schedule where 25% of the options vest after the first year, with the remaining options vesting monthly over the subsequent three years, contingent upon continuous employment with TransMedics. The stock options have a lifespan of 10 years.
Additionally, the compensation package includes 6,670 restricted stock units (RSUs). Similarly, the RSUs are structured to vest 25% annually over four years, also dependent on the employee's ongoing service with the company.
These grants were approved under Nasdaq Listing Rule 5635(c)(4) and are part of the company's Inducement Plan, aimed at attracting and retaining top talent as TransMedics continues to advance its mission of improving organ transplant therapy globally.
